Cargando…

Wound Closure Outcomes Suggest Clinical Equivalency Between Lyopreserved and Cryopreserved Placental Membranes Containing Viable Cells

Objective: To evaluate the clinical outcomes of lyopreserved placental membrane containing viable cells (vLPM) in the treatment of nonhealing wounds of various etiologies, and to compare them to those previously reported for cryopreserved placental membrane containing viable cells (vCPM). Approach:...

Descripción completa

Detalles Bibliográficos
Autores principales: Ananian, Charles E., Davis, R. Daniel, Johnson, Eric L., Regulski, Matthew J., Reyzelman, Alexander M., Saunders, Molly C., Danilkovitch, Alla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798798/
https://www.ncbi.nlm.nih.gov/pubmed/31637101
http://dx.doi.org/10.1089/wound.2019.1028
_version_ 1783460140113985536
author Ananian, Charles E.
Davis, R. Daniel
Johnson, Eric L.
Regulski, Matthew J.
Reyzelman, Alexander M.
Saunders, Molly C.
Danilkovitch, Alla
author_facet Ananian, Charles E.
Davis, R. Daniel
Johnson, Eric L.
Regulski, Matthew J.
Reyzelman, Alexander M.
Saunders, Molly C.
Danilkovitch, Alla
author_sort Ananian, Charles E.
collection PubMed
description Objective: To evaluate the clinical outcomes of lyopreserved placental membrane containing viable cells (vLPM) in the treatment of nonhealing wounds of various etiologies, and to compare them to those previously reported for cryopreserved placental membrane containing viable cells (vCPM). Approach: Patients with nonhealing wounds who qualified to receive advanced wound therapies were consecutively enrolled and treated weekly with vLPM plus standard of care (SOC) at five centers. Data were de-identified and retrospectively analyzed. Outcomes included closure, time to closure, number of vLPM applications, and adverse events (AEs). Results: Seventy-eight patients with 98 wounds (41 diabetic foot ulcers [DFUs], 19 venous leg ulcers [VLUs], 10 surgical, and 28 others) with an average size of 13.3 cm(2) and 8.7 months duration were treated. Fifty-eight of the 98 wounds (59.2%) achieved complete closure with median time to closure of 63 days and 6 vLPM applications. The closure by wound etiology was 63% for DFUs, 47% for VLUs, 70% for surgical wounds, and 57% for other types of wounds. Similar closure rates have been previously demonstrated for vCPM. Wound duration was the main predictor of closure: 65.8% versus 30.0% (p = 0.004) closure was achieved for wounds of ≤12 and >12 months duration, respectively. There were no AEs related to vLPM application. Innovation: This is the first multicenter case series evaluating the clinical outcomes of vLPM in a real-world setting. Conclusion: These results support clinical equivalency between the two placental membrane formulations with the added convenience of room-temperature storage for vLPM, allowing it to be used in any wound-care setting.
format Online
Article
Text
id pubmed-6798798
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Mary Ann Liebert, Inc., publishers
record_format MEDLINE/PubMed
spelling pubmed-67987982019-10-21 Wound Closure Outcomes Suggest Clinical Equivalency Between Lyopreserved and Cryopreserved Placental Membranes Containing Viable Cells Ananian, Charles E. Davis, R. Daniel Johnson, Eric L. Regulski, Matthew J. Reyzelman, Alexander M. Saunders, Molly C. Danilkovitch, Alla Adv Wound Care (New Rochelle) Discovery Express Objective: To evaluate the clinical outcomes of lyopreserved placental membrane containing viable cells (vLPM) in the treatment of nonhealing wounds of various etiologies, and to compare them to those previously reported for cryopreserved placental membrane containing viable cells (vCPM). Approach: Patients with nonhealing wounds who qualified to receive advanced wound therapies were consecutively enrolled and treated weekly with vLPM plus standard of care (SOC) at five centers. Data were de-identified and retrospectively analyzed. Outcomes included closure, time to closure, number of vLPM applications, and adverse events (AEs). Results: Seventy-eight patients with 98 wounds (41 diabetic foot ulcers [DFUs], 19 venous leg ulcers [VLUs], 10 surgical, and 28 others) with an average size of 13.3 cm(2) and 8.7 months duration were treated. Fifty-eight of the 98 wounds (59.2%) achieved complete closure with median time to closure of 63 days and 6 vLPM applications. The closure by wound etiology was 63% for DFUs, 47% for VLUs, 70% for surgical wounds, and 57% for other types of wounds. Similar closure rates have been previously demonstrated for vCPM. Wound duration was the main predictor of closure: 65.8% versus 30.0% (p = 0.004) closure was achieved for wounds of ≤12 and >12 months duration, respectively. There were no AEs related to vLPM application. Innovation: This is the first multicenter case series evaluating the clinical outcomes of vLPM in a real-world setting. Conclusion: These results support clinical equivalency between the two placental membrane formulations with the added convenience of room-temperature storage for vLPM, allowing it to be used in any wound-care setting. Mary Ann Liebert, Inc., publishers 2019-11-01 2019-10-16 /pmc/articles/PMC6798798/ /pubmed/31637101 http://dx.doi.org/10.1089/wound.2019.1028 Text en © Charles E. Ananian, et al. 2019; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Discovery Express
Ananian, Charles E.
Davis, R. Daniel
Johnson, Eric L.
Regulski, Matthew J.
Reyzelman, Alexander M.
Saunders, Molly C.
Danilkovitch, Alla
Wound Closure Outcomes Suggest Clinical Equivalency Between Lyopreserved and Cryopreserved Placental Membranes Containing Viable Cells
title Wound Closure Outcomes Suggest Clinical Equivalency Between Lyopreserved and Cryopreserved Placental Membranes Containing Viable Cells
title_full Wound Closure Outcomes Suggest Clinical Equivalency Between Lyopreserved and Cryopreserved Placental Membranes Containing Viable Cells
title_fullStr Wound Closure Outcomes Suggest Clinical Equivalency Between Lyopreserved and Cryopreserved Placental Membranes Containing Viable Cells
title_full_unstemmed Wound Closure Outcomes Suggest Clinical Equivalency Between Lyopreserved and Cryopreserved Placental Membranes Containing Viable Cells
title_short Wound Closure Outcomes Suggest Clinical Equivalency Between Lyopreserved and Cryopreserved Placental Membranes Containing Viable Cells
title_sort wound closure outcomes suggest clinical equivalency between lyopreserved and cryopreserved placental membranes containing viable cells
topic Discovery Express
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798798/
https://www.ncbi.nlm.nih.gov/pubmed/31637101
http://dx.doi.org/10.1089/wound.2019.1028
work_keys_str_mv AT ananiancharlese woundclosureoutcomessuggestclinicalequivalencybetweenlyopreservedandcryopreservedplacentalmembranescontainingviablecells
AT davisrdaniel woundclosureoutcomessuggestclinicalequivalencybetweenlyopreservedandcryopreservedplacentalmembranescontainingviablecells
AT johnsonericl woundclosureoutcomessuggestclinicalequivalencybetweenlyopreservedandcryopreservedplacentalmembranescontainingviablecells
AT regulskimatthewj woundclosureoutcomessuggestclinicalequivalencybetweenlyopreservedandcryopreservedplacentalmembranescontainingviablecells
AT reyzelmanalexanderm woundclosureoutcomessuggestclinicalequivalencybetweenlyopreservedandcryopreservedplacentalmembranescontainingviablecells
AT saundersmollyc woundclosureoutcomessuggestclinicalequivalencybetweenlyopreservedandcryopreservedplacentalmembranescontainingviablecells
AT danilkovitchalla woundclosureoutcomessuggestclinicalequivalencybetweenlyopreservedandcryopreservedplacentalmembranescontainingviablecells